Profusa, Inc. announced that it has received a notice from Nasdaq stating that after its 1-for-4 reverse stock split on August 14, 2026, it fell below the required 500,000 publicly held shares, but following correspondence on August 21, 2026, Nasdaq determined the company complies with the rule and has closed its review. The notice does not affect the listing or trading of Profusa's securities, which continue on the Nasdaq Capital Market under the symbol PFSA. The company made the announcement in accordance with Nasdaq Listing Rule 5810(b), which mandates prompt disclosure of deficiency notifications. Profusa, based in Berkeley, California, develops tissue-integrated biosensors for medical and personal use.
Profusa, Inc. Common StockNasdaq determined Profusa regained compliance with the 500,000 publicly held shares rule after its reverse split, closing the deficiency review.